Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Mukaida, Naofumi ^a,b   Sasaki, So Ichiro ^a,b   Baba, Tomohisa ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

CANCER CELL; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; ENDOTHELIUM CELL; FIBROBLAST; LEUKOCYTE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; SUPPRESSOR CELL; TUMOR IMMUNITY; ANIMAL; CELL MOTION; CHEMISTRY; CYTOLOGY; DENDRITIC CELL; DISEASE COURSE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; METASTASIS; MOUSE; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CHEMOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LEUKOCYTES; MACROPHAGES; MICE; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84902171144     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/170381     Document Type: Review

References (124)

1. Moser B., Wolf M., Walz A., Loetscher P., Chemokines: multiple levels of leukocyte migration control. Trends in Immunology 2004 25 2 75 84 2-s2.0-0842324615 10.1016/j.it.2003.12.005
2. Fernandez E. J., Lolis E., Structure, function, and inhibition of chemokines. Annual Review of Pharmacology and Toxicology 2002 42 469 499 2-s2.0-0036178483 10.1146/annurev.pharmtox.42.091901.115838
3. Vandercappellen J., van Damme J., Struyf S., The role of CXC chemokines and their receptors in cancer. Cancer Letters 2008 267 2 226 244 2-s2.0-47749109823 10.1016/j.canlet.2008.04.050
4. Zlotnik A., Yoshie O., The chemokine superfamily revisited. Immunity 2012 36 5 705 716 10.1016/j.immuni.2012.05.008
5. Nomiyama H., Osada N., Yoshie O., The evolution of mammalian chemokine genes. Cytokine and Growth Factor Reviews 2010 21 4 253 262 2-s2.0-77956406542 10.1016/j.cytogfr.2010.03.004
6. Moepps B., Nuesseler E., Braun M., Gierschik P., A homolog of the human chemokine receptor CXCR1 is expressed in the mouse. Molecular Immunology 2006 43 7 897 914 2-s2.0-29144467674 10.1016/j.molimm.2005.06.043
7. Su S.-B., Mukaida N., Wang J., Nomura H., Matsushima K., Preparation of specific antagonizing polyclonal antibodies to a C-C chemokine receptor, CCR1 and determination of its distribution of various types of leukocytes. Journal of Leukocyte Biology 1996 60 5 658 666
8. Sica A., Allavena P., Mantovani A., Cancer related inflammation: the macrophage connection. Cancer Letters 2008 267 2 204 215 2-s2.0-47749155653 10.1016/j.canlet.2008.03.028
9. Lazennec G., Richmond A., Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in Molecular Medicine 2010 16 3 133 144 2-s2.0-77949329326 10.1016/j.molmed.2010.01.003
10. Popivanova B. K., Kostadinova F. I., Furuichi K., Shamekh M. M., Kondo T., Wada T., Egashira K., Mukaida N., Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Research 2009 69 19 7884 7892 2-s2.0-70350227255 10.1158/0008-5472.CAN-09-1451
11. Qian B. Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L. R., Kaiser E. A., Snyder L. A., Pollard J. W., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011 475 7355 222 225 2-s2.0-79960411324 10.1038/nature10138
12. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 2002 23 11 549 555 2-s2.0-0036839143 10.1016/S1471-4906(02)02302-5
13. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009 9 3 162 174 2-s2.0-61349100687 10.1038/nri2506
14. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.-M., Feng Z.-H., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Letters 2007 252 1 86 92 2-s2.0-34248328368 10.1016/j.canlet.2006.12.012
15. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J. E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K., Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008 111 12 5457 5466 2-s2.0-47049126742 10.1182/blood-2008-01-136895
16. Katoh H., Wang D., Daikoku T., Sun H., Dey S. K., DuBois R. N., CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013 24 3 631 644 10.1016/j.ccr.2013.10.009
17. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity. International Journal of Cancer 2010 127 4 759 767 2-s2.0-77954721060 10.1002/ijc.25429
18. Facciabene A., Peng X., Hagemann I. S., Balint K., Barchetti A., Wang L. P., Gimotty P. A., Gilks C. B., Lal P., Zhang L., Coukos G., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells. Nature 2011 475 7355 226 230 2-s2.0-79960393113 10.1038/nature10169
19. Bindea G., Miecnik B., Tosolini M., Spaciotemporal dynamics of intratumoral immune cells reveals the immune landscape in human cancer. Immunity 2013 39 4 782 795 10.1016/j.immuni.2013.10.003
20. Steer H. J., Lake R. A., Nowak A. K., Robinson B. W., Harnessing the immune response to treat cancer. Oncogene 2010 29 48 6301 6313 2-s2.0-78649814615 10.1038/onc.2010.437
21. Knutson K. L., Disis M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunology and Immunotherapy 2005 54 8 721 728 2-s2.0-22144439081 10.1007/s00262-004-0653-2
22. Palucka K., Banchereau J., Cancer immunotherapy via dendritic cells. Nature Reviews Cancer 2012 12 4 265 277 2-s2.0-84858780815 10.1038/nrc3258
23. Sozzani S., Dendritic cell trafficking: more than just chemokines. Cytokine and Growth Factor Reviews 2005 16 6 581 592 2-s2.0-27144525192 10.1016/j.cytogfr.2005.04.008
24. Iida N., Nakamoto Y., Baba T., Kakinoki K., Li Y. Y., Wu Y., Matsushima K., Kaneko S., Mukaida N., Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. Journal of Leukocyte Biology 2008 84 4 1001 1010 2-s2.0-57149109833 10.1189/jlb.1107791
25. Gooden M. J., de Bock G. H., Leffers N., Daemen T., Nijman H. W., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. The British Journal of Cancer 2011 105 1 93 103 2-s2.0-79959745851 10.1038/bjc.2011.189
26. Pan J., Burdick M. D., Belperio J. A., Xue Y. Y., Gerard C., Sharma S., Dubinett S. M., Strieter R. M., CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. Journal of Immunology 2006 176 3 1456 1464 2-s2.0-31144468057
27. + T lymphocytes in human colorectal carcinoma. International Journal of Cancer 2005 116 6 949 956 2-s2.0-23944469303 10.1002/ijc.21135
28. + T cells in lymphocyte-rich gastric carcinoma. Journal of Pathology 2009 217 1 21 31 2-s2.0-58649094649 10.1002/path.2448
29. Muthuswamy R., Berk E., Junecko B. F., NF- B hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Research 2012 72 15 3735 3743 10.1158/0008-5472.CAN-11-4136
30. Ohta M., Tanaka F., Yamaguchi H., Sadanaga N., Inoue H., Mori M., The high expression of fractalkine results in a better prognosis for colorectal cancer patients. International Journal of Oncology 2005 26 1 41 47 2-s2.0-20444479181
31. Hojo S., Koizumi K., Tsuneyama K., Arita Y., Cui Z., Shinohara K., Minami T., Hashimoto I., Nakayama T., Sakurai H., Takano Y., Yoshie O., Tsukada K., Saiki I., High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Research 2007 67 10 4725 4731 2-s2.0-34250373206 10.1158/0008-5472.CAN-06-3424
32. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S., Functions of natural killer cells. Nature Immunology 2008 9 5 503 510 2-s2.0-42449151214 10.1038/ni1582
33. Walzer T., Vivier E., G-protein-coupled receptors in control of natural killer cell migration. Trends in Immunology 2011 32 10 486 492 2-s2.0-80053321471 10.1016/j.it.2011.05.002
34. Halama N., Braun M., Kahlert C., Spille A., Quack C., Rahbari N., Koch M., Weitz J., Kloor M., Zoernig I., Schirmacher P., Brand K., Grabe N., Falk C. S., Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clinical Cancer Research 2011 17 4 678 689 2-s2.0-79951824956 10.1158/1078-0432.CCR-10-2173
35. Baba T., Naka L., Morishita S., Komatsu N., Hirao A., Mukaida N., MIP-1 α /CCL3-mediated maintenance of leukemia initiating cells in the initiation process of chronic leukemia. Journal of Experimental Medicine 2013 210 12 2661 2673 10.1084/jem.20130112
36. Fidler I. J., Ellis L. M., The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994 79 2 185 188 2-s2.0-0028114985 10.1016/0092-8674(94)90187-2
37. Keeley E. C., Mehrad B., Strieter R. M., Chemokines as mediators of tumor angiogenesis and neovascularization. Experimental Cell Research 2011 317 5 685 690 2-s2.0-79952103672 10.1016/j.yexcr.2010.10.020
38. Teicher B. A., Fricker S. P., CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical Cancer Research 2010 16 11 2927 2931 2-s2.0-77953090345 10.1158/1078-0432.CCR-09-2329
39. Gálvez B. G., Genís L., Matías-Román S., Oblander S. A., Tryggvason K., Apte S. S., Arroyo A. G., Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/CCL2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. The Journal of Biological Chemistry 2005 280 2 1292 1298 2-s2.0-12544257156 10.1074/jbc.M408673200
40. + endothelial cells. Journal of Immunology 2001 166 12 7571 7578 2-s2.0-0035877258
41. Strasly M., Doronzo G., Cappello P., Valdembri D., Arese M., Mitola S., Moore P., Alessandri G., Giovarelli M., Bussolino F., CCL16 activates an angiogenic program in vascular endothelial cells. Blood 2004 103 1 40 49 2-s2.0-9144259213 10.1182/blood-2003-05-1387
42. Maione T. E., Gray G. S., Petro J., Hunt A. J., Donner A. L., Bauer S. I., Carson H. F., Sharpe R. J., Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990 247 4938 77 79 2-s2.0-0025166396
43. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., Uguccioni M., Galli G., Cosmi L., Maurenzig L., Baggiolini M., Maggi E., Romagnani S., Serio M., Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. Journal of Clinical Investigation 2001 107 1 53 63 2-s2.0-0035173672
44. Du J., Luan J., Liu H., Daniel T. O., Peiper S., Chen T. S., Yu Y., Horton L. W., Nanney L. B., Strieter R. M., Richmond A., Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. Journal of Leukocyte Biology 2002 71 1 141 153 2-s2.0-0036144089
45. Rehman J., Li J., Orschell C. M., March K. L., Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003 107 8 1164 1169 2-s2.0-0037418213 10.1161/01.CIR.0000058702.69484.A0
46. Gijsbers K., Gouwy M., Struyf S., Wuyts A., Proost P., Opdenakker G., Penninckx F., Ectors N., Geboes K., van Damme J., GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Experimental Cell Research 2005 303 2 331 342 2-s2.0-19944430168 10.1016/j.yexcr.2004.09.027
47. Räsänen K., Vaheri A., Activation of fibroblasts in cancer stroma. Experimental Cell Research 2010 316 17 2713 2722 2-s2.0-77956883321 10.1016/j.yexcr.2010.04.032
48. Mishra P., Banerjee D., Ben-Baruch A., Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. Journal of Leukocyte Biology 2011 89 1 31 39 2-s2.0-78649637459 10.1189/jlb.0310182
49. Guo X., Oshima H., Kitmura T., Taketo M. M., Oshima M., Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. The Journal of Biological Chemistry 2008 283 28 19864 19871 2-s2.0-50349101081 10.1074/jbc.M800798200
50. Wu Y., Li Y. Y., Matsushima K., Baba T., Mukaida N., CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. Journal of Immunology 2008 181 9 6384 6393 2-s2.0-58749093606
51. Matsusue R., Kubo H., Hisamori S., Okoshi K., Takagi H., Hida K., Nakano K., Itami A., Kawada K., Nagayama S., Sakai Y., Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Annals of Surgical Oncology 2009 16 9 2645 2653 2-s2.0-68949200810 10.1245/s10434-009-0599-x
52. Yang X., Lu P., Ishida Y., Kuziel W. A., Fujii C., Mukaida N., Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization. International Journal of Cancer 2006 118 2 335 345 2-s2.0-28844443794 10.1002/ijc.21371
53. Borrello M. G., Alberti L., Fischer A., Degl'Innocenti D., Ferrario C., Gariboldi M., Marchesi F., Allavena P., Greco A., Collini P., Pilotti S., Cassinelli G., Bressan P., Fugazzola L., Mantovani A., Pierotti M. A., Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America 2005 102 41 14825 14830 2-s2.0-26844576749 10.1073/pnas.0503039102
54. Schioppa T., Uranchimeg B., Saccani A., Biswas S. K., Doni A., Rapisarda A., Bernasconi S., Saccani S., Nebuloni M., Vago L., Mantovani A., Melillo G., Sica A., Regulation of the chemokine receptor CXCR4 by hypoxia. Journal of Experimental Medicine 2003 198 9 1391 1402 2-s2.0-10744219598 10.1084/jem.20030267
55. Ben-Neriah Y., Karin M., Inflammation meets cancer, with NF- B as the matchmaker. Nature Immunology 2011 12 8 715 723 2-s2.0-80052014052 10.1038/ni.2060
56. Hold G. L., El-Omar E. M., Genetic aspects of inflammation and cancer. Biochemical Journal 2008 410 2 225 235 2-s2.0-40449087027 10.1042/BJ20071341
57. Kuilman T., Michaloglou C., Mooi W. J., Peeper D. S., The essence of senescence. Genes and Development 2010 24 22 2463 2479 2-s2.0-78349257844 10.1101/gad.1971610
58. Kuilman T., Michaloglou C., Vredeveld L. C., Douma S., van Doorn R., Desmet C. J., Aarden L. A., Mooi W. J., Peeper D. S., Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008 133 6 1019 1031 2-s2.0-44649101304 10.1016/j.cell.2008.03.039
59. Acosta J. C., O'Loghlen A., Banito A., Guijarro M. V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., Takatsu Y., Melamed J., d'Adda di Fagagna F., Bernard D., Hernando E., Gil J., Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008 133 6 1006 1018 2-s2.0-44649120132 10.1016/j.cell.2008.03.038
60. Thiery J. P., Acloque H., Huang R. Y., Nieto M. A., Epithelial- mesenchymal transitions in development and disease. Cell 2009 139 5 871 890 2-s2.0-70450198396 10.1016/j.cell.2009.11.007
61. Bertran E., Caja L., Navarro E., Sancho P., Mainez J., Murillo M. M., Vinyals A., Fabra À., Fabregat I., Role of CXCR4/SDF-1 α in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor- β Cellular Signalling 2009 21 11 1595 1606 2-s2.0-69049109696 10.1016/j.cellsig.2009.06.006
62. Bates R. C., Deleo M. J. III, Mercurio A. M., The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Experimental Cell Research 2004 299 2 315 324 2-s2.0-4444319419 10.1016/j.yexcr.2004.05.033
63. Fernando R. I., Castillo M. D., Litzinger M., Hamilton D. H., Palena C., IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Research 2011 71 15 5296 5306 2-s2.0-79960952144 10.1158/0008-5472.CAN-11-0156
64. Allavena P., Germano G., Marchesi F., Mantovani A., Chemokines in cancer related inflammation. Experimental Cell Research 2011 317 5 664 673 2-s2.0-79952090185 10.1016/j.yexcr.2010.11.013
65. Kitadai Y., Haruma K., Mukaida N., Ohmoto Y., Matsutani N., Yasui W., Yamamoto S., Sumii K., Kajiyama G., Fidler I. J., Tahara E., Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clinical Cancer Research 2000 6 7 2735 2740 2-s2.0-0033939968
66. Wang B., Hendricks D. T., Wamunyokoli F., Parker M. I., A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Research 2006 66 6 3071 3077 2-s2.0-33645509280 10.1158/0008-5472.CAN-05-2871
67. Singh S., Nannuru K. C., Sadanandam A., Varney M. L., Singh R. K., CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. The British Journal of Cancer 2009 100 10 1638 1646 2-s2.0-67349108316 10.1038/sj.bjc.6605055
68. Ghadjar P., Rubie C., Aebersold D. M., Keilholz U., The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. International Journal of Cancer 2009 125 4 741 745 2-s2.0-67650022084 10.1002/ijc.24468
69. Darash-Yahana M., Gillespie J. W., Hewitt S. M., Chen Y. Y. K., Maeda S., Stein I., Singh S. P., Bedolla R. B., Peled A., Troyer D. A., Pikarsky E., Karin M., Farber J. M., The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS ONE 2009 4 8 2-s2.0-68949215694 10.1371/journal.pone.0006695 e6695
70. Murakami T., Cardones A. R., Finkelstein S. E., Restifo N. P., Klaunberg B. A., Nestle F. O., Castillo S. S., Dennis P. A., Hwang S. T., Immune evasion by murine melanoma mediated through CC chemokine receptor-10. Journal of Experimental Medicine 2003 198 9 1337 1347 2-s2.0-0242611008 10.1084/jem.20030593
71. Wang J., Seethala R. R., Zhang Q., Gooding W., van Waes C., Hasegawa H., Ferris R. L., Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. Journal of the National Cancer Institute 2008 100 7 502 512 2-s2.0-41749086697 10.1093/jnci/djn059
72. Mañes S., Mira E., Colomer R., Montero S., Real L. M., Gómez-Moutón C., Jiménez-Baranda S., Garzón A., Lacalle R. A., Harshman K., Ruíz A., Martínez-A C., CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. Journal of Experimental Medicine 2003 198 9 1381 1389 2-s2.0-16744362709 10.1084/jem.20030580
73. Lu P., Nakamoto Y., Nemoto-Sasaki Y., Fujii C., Wang H., Hashii M., Ohmoto Y., Kaneko S., Kobayashi K., Mukaida N., Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. The American Journal of Pathology 2003 162 4 1249 1258 2-s2.0-0344837388
74. Righi E., Kashiwagi S., Yuan J., Santosuosso M., Leblanc P., Ingraham R., Forbes B., Edelblute B., Collette B., Xing D., Kowalski M., Mingari M. C., Vianello F., Birrer M., Orsulic S., Dranoff G., Poznansky M. C., CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Research 2011 71 16 5522 5534 2-s2.0-80051690814 10.1158/0008-5472.CAN-10-3143
75. Messmer D., Fecteau J.-F., O'Hayre M., Bharati I. S., Handel T. M., Kipps T. J., Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011 117 3 882 889 2-s2.0-78751684268 10.1182/blood-2010-04-282400
76. Zhang Y., Zhao H., Zhao D., Sun L., zhi Y., Wu X., Huang W., Da W., SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. Leukemia Research 2012 36 3 281 286 2-s2.0-82855163261 10.1016/j.leukres.2011.06.017
77. Müller A., Homey B., Soto H., Involvement of chemokine receptors in breast cancer metastasis. Nature 2001 410 6824 50 56 10.1038/35065016
78. Amersi F. F., Terando A. M., Goto Y., Scolyer R. A., Thompson J. F., Tran A. N., Faries M. B., Morton D. L., Hoon D. S. B., Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clinical Cancer Research 2008 14 3 638 645 2-s2.0-38949129112 10.1158/1078-0432.CCR-07-2025
79. Waugh D. J., Wilson C., The interleukin-8 pathway in cancer. Clinical Cancer Research 2008 14 21 6735 6741 2-s2.0-58149232586 10.1158/1078-0432.CCR- 07-4843
80. Marchesi F., Piemonti L., Fedele G., Destro A., Roncalli M., Albarello L., Doglioni C., Anselmo A., Doni A., Bianchi P., Laghi L., Malesci A., Cervo L., Malosio M., Reni M., Zerbi A., Di Carlo V., Mantovani A., Allavena P., The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Research 2008 68 21 9060 9069 2-s2.0-55349148665 10.1158/0008-5472.CAN-08-1810
81. Yoshie O., Fujisawa R., Nakayama T., Harasawa H., Tago H., Izawa D., Hieshima K., Tatsumi Y., Matsushima K., Hasegawa H., Kanamaru A., Kamihira S., Yamada Y., Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002 99 5 1505 1511 2-s2.0-0036493316 10.1182/blood.V99.5.1505
82. Kim M. Y., Oskarsson T., Acharyya S., Nguyen D. X., Zhang X. H.-F., Norton L., Massagué J., Tumor self-seeding by circulating cancer cells. Cell 2009 139 7 1315 1326 2-s2.0-72249093615 10.1016/j.cell.2009.11.025
83. Shields J. D., Fleury M. E., Yong C., Tomei A. A., Randolph G. J., Swartz M. A., Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 singaling. Cancer Cell 2007 11 6 526 538 2-s2.0-34249774277 10.1016/j.ccr.2007.04.020
84. Zhang X. H., Wang Q., Gerald W., Hudis C. A., Norton L., Smid M., Foekens J. A., Massagué J., Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009 16 1 67 78 2-s2.0-67649311599 10.1016/j.ccr.2009.05.017
85. Kochetkova M., Kumar S., McColl S. R., Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death and Differentiation 2009 16 5 664 673 2-s2.0-67349256382 10.1038/cdd.2008.190
86. Zhang Y., Yoneyama H., Wang Y., Ishikawa S., Hashimoto S.-I., Gao J.-L., Murphy P., Matsushima K., Mobilization of dendritic cell precursors into the circulation by administration of MIP-1 α in mice. Journal of the National Cancer Institute 2004 96 3 201 209 2-s2.0-1342284860
87. Iida N., Nakamoto Y., Baba T., Nakagawa H., Mizukoshi E., Naito M., Mukaida N., Kaneko S., Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC chemokine ligand 3/macrophage inflammatory protein-1 α Cancer Research 2010 70 16 6556 6565 2-s2.0-77955741107 10.1158/0008-5472.CAN-10-0096
88. Förster R., Schubel A., Breitfeld D., Kremmer E., Renner-Müller I., Wolf E., Lipp M., CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999 99 1 23 33 2-s2.0-0033214348 10.1016/S0092-8674(00)80059-8
89. Sharma S., Stolina M., Zhu L., Lin Y., Batra R., Huang M., Strieter R., Dubinett S. M., Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Research 2001 61 17 6406 6412 2-s2.0-0035417890
90. Hillinger S., Yang S. C., Batra R. K., Strieter R. M., Weder W., Dubinett S. M., Sharma S., CCL19 reduces tumour burden in a model of advanced lung cancer. The British Journal of Cancer 2006 94 7 1029 1034 2-s2.0-33645736489 10.1038/sj.bjc.6603061
91. Chang A. E., Redman B. G., Whitfield J. R., Nickoloff B. J., Braun T. M., Lee P. P., Geiger J. D., Mulé J. J., A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clinical Cancer Research 2002 8 4 1021 1032 2-s2.0-0036554831
92. Kirk C. J., Hartigan-O'Connor D., Nickoloff B. J., Chamberlain J. S., Giedlin M., Aukerman L., Mulé J. J., T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Research 2001 61 5 2062 2070 2-s2.0-0035266293
93. Kirk C. J., Hartigan-O'Connor D., Mulé J. J., The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Research 2001 61 24 8794 8802 2-s2.0-0035893749
94. Baratelli F., Takedatsu H., Hazra S., Peebles K., Luo J., Kurimoto P. S., Zeng G., Batra R. K., Sharma S., Dubinett S. M., Lee J. M., Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. Journal of Translational Medicine 2008 6, article 38 2-s2.0-49649091143 10.1186/1479-5876-6-38
95. Yang S. C., Hillinger S., Riedl K., Zhang L., Zhu L., Huang M., Atianzar K., Kuo B. Y., Gardner B., Batra R. K., Strieter R. M., Dubinett S. M., Sharma S., Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clinical Cancer Research 2004 10 8 2891 2901 2-s2.0-11144358381 10.1158/1078-0432.CCR-03- 0380
96. Groom J. R., Luster A. D., CXCR3 in T cell function. Experimental Cell Research 2011 317 5 620 631 2-s2.0-79952091851 10.1016/j.yexcr.2010.12.017
97. Luster A. D., Leder P., IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. Journal of Experimental Medicine 1993 178 3 1057 1065 2-s2.0-0027169811
98. Yang X., Chu Y., Wang Y., Zhang R., Xiong S., Targeted in vivo expression of IFN- γ -inducible protein 10 induces specific antitumor activity. Journal of Leukocyte Biology 2006 80 6 1434 1444 2-s2.0-33845460155 10.1189/jlb.0306212
99. Hensbergen P. J., Wijnands P. G., Schreurs M. W., Scheper R. J., Willemze R., Tensen C. P., The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Journal of Immunotherapy 2005 28 4 343 351 2-s2.0-21844433463
100. Matsushima K., Larsen C. G., DuBois G. C., Oppenheim J. J., Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. Journal of Experimental Medicine 1989 169 4 1485 1490 2-s2.0-0024508563
101. Rollins B. J., Sunday M. E., Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Molecular and Cellular Biology 1991 11 6 3125 3131 2-s2.0-0025845388
102. Nokihara H., Yanagawa H., Nishioka Y., Yano S., Mukaida N., Matsushima K., Sone S., Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Research 2000 60 24 7002 7007 2-s2.0-0034671222
103. Tsuchiyama T., Nakamoto Y., Sakai Y., Marukawa Y., Kitahara M., Mukaida N., Kaneko S., Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. Journal of Immunology 2007 178 1 574 583 2-s2.0-33845929522
104. Lavergne E., Combadière B., Bonduelle O., Iga M., Gao J.-L., Maho M., Boissonnas A., Murphy P. M., Debré P., Combadière C., Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Research 2003 63 21 7468 7474 2-s2.0-0242442490
105. Tang L., Hu H. D., Hu P., Lan Y.-H., Peng M.-L., Chen M., Ren H., Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Therapy 2007 14 16 1226 1234 2-s2.0-34547739550 10.1038/sj.gt.3302959
106. Zeng Y., Huebener N., Fest S., Weixler S., Schroeder U., Gaedicke G., Xiang R., Schramm A., Eggert A., Reisfeld R. A., Lode H. N., Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Research 2007 67 5 2331 2338 2-s2.0-33947289558 10.1158/0008-5472.CAN-06-3041
107. Iga M., Boissonnas A., Mahé B., Bonduelle O., Combadière C., Combadière B., Single CX3CL1-Ig DNA administration enhances T cell priming in vivo. Vaccine 2007 25 23 4554 4563 2-s2.0-34248376567 10.1016/j.vaccine.2007.04.028
108. van den Berg A., Visser L., Poppema S., High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. The American Journal of Pathology 1999 154 6 1685 1691 2-s2.0-0033058533
109. di Stasi A., de Angelis B., Rooney C. M., Zhang L., Mahendravada A., Foster A. E., Heslop H. E., Brenner M. K., Dotti G., Savoldo B., T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009 113 25 6392 6402 2-s2.0-67650638846 10.1182/blood-2009-03-209650
110. Moon E. K., Carpenito C., Sun J., Wang L.-C. S., Kapoor V., Predina J., Powell D. J. Jr., Riley J. L., June C. H., Albelda S. M., Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clinical Cancer Research 2011 17 14 4719 4730 2-s2.0-79960403269 10.1158/1078-0432.CCR-11-0351
111. Sarnaik A. A., Weber J. S., Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer Journal 2009 15 3 169 173 2-s2.0-67651146461 10.1097/PPO.0b013e3181a7450f
112. Ribas A., Tumor immunotherapy directed at PD-1. The New England Journal of Medicine 2012 366 26 2517 2519 10.1056/NEJMe1205943
113. Loberg R. D., Ying C., Craig M., Day L. L., Sargent E., Neeley C., Wojno K., Snyder L. A., Yan L., Pienta K. J., Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research 2007 67 19 9417 9424 2-s2.0-35148852659 10.1158/0008-5472.CAN- 07-1286
114. + myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Research 2012 72 4 876 886 2-s2.0-84857219446 10.1158/0008-5472.CAN-11-1792
115. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., Suttmann H., Schenck M., Welling J., Zabel P., Lang S., Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. Journal of Leukocyte Biology 2011 89 2 311 317 2-s2.0-79951823584 10.1189/jlb.0310162
116. Ishida T., Ueda R., Antibody therapy for adult T-cell leukemia-lymphoma. International Journal of Hematology 2011 94 5 443 452 2-s2.0-84355162957 10.1007/s12185-011-0941-5
117. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004 10 9 942 949 2-s2.0-4644237613 10.1038/nm1093
118. + regulatory T cells, evoking antitumor responses in humans. Proceeding of National Academy of Science of the United States of America 2013 110 44 17945 17950 10.1073/pnas.1316796110
119. Fridlender Z. G., Buchlis G., Kapoor V., Cheng G., Sun J., Singhal S., Crisanti M. C., Wang L.-C. S., Heitjan D., Snyder L. A., Albelda S. M., CCL2 blockade augments cancer immunotherapy. Cancer Research 2010 70 1 109 118 2-s2.0-77950252788 10.1158/0008-5472.CAN-09-2326
120. + myeloid cells that promote invasion. Nature Genetics 2007 39 4 467 475 2-s2.0-34047138860 10.1038/ng1997
121. Kitamura T., Fujishita T., Loetscher P., Revesz L., Hashida H., Kizaka-Kondoh S., Aoki M., Taketo M. M., Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in amouse model. Proceedings of the National Academy of Sciences of the United States of America 2010 107 29 13063 13068 2-s2.0-77955640339 10.1073/pnas.1002372107
122. Arenberg D. A., Kunkel S. L., Polverini P. J., Glass M., Burdick M. D., Strieter R. M., Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. Journal of Clinical Investigation 1996 97 12 2792 2802 10.1172/JCI118734
123. Kryczek I., Wei S., Keller E., Liu R., Zou W., Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. The American Journal of Physiology-Cell Physiology 2007 292 3 C987 C995 2-s2.0-33947310596 10.1152/ajpcell.00406.2006
124. Addison C. L., Arenberg D. A., Morris S. B., Xue Y.-Y., Burdick M. D., Mulligan M. S., Iannettoni M. D., Strieter R. M., The CXC chemokine, monokine induced by interferon- γ inhibits non-small cell lung carcinoma tumor growth and metastasis. Human Gene Therapy 2000 11 2 247 261 2-s2.0-0034688120 10.1089/10430340050015996